KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Cash & Equivalents (2016 - 2025)

Rigel Pharmaceuticals has reported Cash & Equivalents over the past 16 years, most recently at $40.6 million for Q4 2025.

  • Quarterly results put Cash & Equivalents at $40.6 million for Q4 2025, down 28.49% from a year ago — trailing twelve months through Dec 2025 was $40.6 million (down 28.49% YoY), and the annual figure for FY2025 was $40.6 million, down 28.49%.
  • Cash & Equivalents for Q4 2025 was $40.6 million at Rigel Pharmaceuticals, down from $48.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for RIGL hit a ceiling of $84.8 million in Q2 2021 and a floor of $18.9 million in Q4 2021.
  • Median Cash & Equivalents over the past 5 years was $38.2 million (2023), compared with a mean of $39.3 million.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 132.59% in 2021 and later tumbled 67.93% in 2022.
  • Rigel Pharmaceuticals' Cash & Equivalents stood at $18.9 million in 2021, then grew by 29.48% to $24.5 million in 2022, then soared by 34.04% to $32.8 million in 2023, then soared by 73.08% to $56.7 million in 2024, then fell by 28.49% to $40.6 million in 2025.
  • The last three reported values for Cash & Equivalents were $40.6 million (Q4 2025), $48.5 million (Q3 2025), and $53.4 million (Q2 2025) per Business Quant data.